Cannabinoids (CBD)

SUDA finalised the Product Development, Licence and Supply Agreement with Cann Pharmaceutical Australia Ltd (CPA) in October 2019. The Agreement is to develop a novel oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of: drug resistant epilepsy, melanoma and motion sickness throughout the world.